UPDATE DND

The appeal against DND was rejected thus minimizing the possibility of further court actions.

With that decision and the fact that they have a product ready to be launched in the USA DND is no a longer a speculative play but now part of my TOP PICKS for 2010.

They will receive more upfront payments from Ranbaxy (up to 23M$ before and after launch) and some royalties from the sales in USA and territories.

Also to be noted is that other expenses will also be reimbursed by Ranbaxy.  DND has actually about 9M$ in their bacnk account and when you add the payments that should be paid this year, DND could end up Q4 with 20M$ in the bacnk almost a 1 for 1 ration to their share actual value.

Just that fact alone could boost the shares to well over 3$ before year end for a whoppping 300% return.

As usual, DO NOT INVEST more than what you can afford to lose.